Sökning: onr:"swepub:oai:DiVA.org:liu-117376" >
Enhanced anti-tumor...
Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D, L-lactic-co-glycolic) acid nanoparticles nanoparticles
-
- Campbell, Diahnn (författare)
- University of Calif San Diego, CA 92093 USA
-
- Saenz, Rebecca (författare)
- University of Calif San Diego, CA 92093 USA
-
- Bharati, Ila S. (författare)
- University of Calif San Diego, CA 92093 USA
-
visa fler...
-
- Seible, Daniel (författare)
- University of Calif San Diego, CA 92093 USA
-
- Zhang, Liangfang (författare)
- University of Calif San Diego, CA 92093 USA
-
- Esener, Sadik (författare)
- University of Calif San Diego, CA 92093 USA
-
- Messmer, Bradley (författare)
- University of Calif San Diego, CA 92093 USA
-
- Larsson, Marie (författare)
- Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Hälsouniversitetet
-
- Messmer, Davorka (författare)
- University of Calif San Diego, CA 92093 USA
-
visa färre...
-
(creator_code:org_t)
- 2015-03-31
- 2015
- Engelska.
-
Ingår i: Breast Cancer Research. - : BioMed Central. - 1465-5411 .- 1465-542X. ; 17:48
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://breast-cance...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as potent immune adjuvant. Method In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2) positive breast cancer. Results Free peptide did not significantly augment immune responses but, when delivered in poly(D, L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2 specific T cells was observed in vitro. Vaccination of HER2NEU transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91 loaded PLGA-NPs enhanced the activation of HER2 specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusion Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas